EMPOWERING COMMUNITIES AGAINST COVID-19:
THE PANORAMIC APPROACH

 

THE PANORAMIC STUDY

Despite high uptake of vaccination against Covid-19, the disease remains prevalent in the UK and in many countries across the world, with many patients continuing to experience considerable morbidity and require treatment in hospital. There is therefore an urgent need to identify treatments for Covid-19 for use in the community early on in the illness that speeds recovery and prevents the need for hospital admission.

REPORT

Primary Outcome: all-cause, non-elective hospitalisation and/or death within 28 days of randomisation.

CASE STUDY

“In clinical trials, we don't often have the luxury of a full system that will do everything for us. Normally there would be a separate system for separate things. Spiral provides this full system”

LY-MEE YU, LEAD STATISTICIAN, PANORAMIC TRIAL

LATEST UPDATE

After over two years, 29,295 participants across 72 sites, the PANORAMIC trial has officially closed to recruitment. This was the biggest COVID-19 trial in the community ever. Data will continue to be collected until September 2024 and results will be shared.

BACKGROUND

  • Despite high uptake of vaccination against COVID-19, the disease remains prevalent in the UK and in many countries around the world, with many patients continuing to experience considerable morbidity and require treatment in hospital. There is therefore an urgent need to identify treatments for COVID-19 for use in the community early on in the illness that speeds recovery and prevents the need for hospital admission.

  • A UK-wide clinical study sponsored by the University of Oxford and funded by the National Institute for Health and Care Research.

  • This trial can be carried out remotely. This means that participants can contribute to the study from home, with all packs posted directly from the trial team. Questionnaires and diaries can be filled out online or if needed via phone call with a PANORAMIC team member.

TRIAL DESIGN

  • A “platform trial” a trial in which multiple treatments for the same disease can be tested simultaneously, and in which new interventions can be added or replace existing ones during the course of the trial in accordance with pre-specified criteria.

  • Participants will be randomised to receive either Usual Care, or an antiviral agent in addition to Usual Care.

  • Potential participants can be included if they are eligible to be randomised to at least one novel antiviral agent, as well as the Usual Care arm.

SUPPORTERS

Substudies:

  • The Post Exposure Prophylaxis sub-study will test whether antiviral agents prevent transmission to people living with someone who gets COVID-19.

  • A Virology sub-study which aims to find out whether the new treatments reduce viral shedding and if using the new drugs cause the virus to become resistant to treatment.

  • Our Spiral Technical Lead for the PANORAMIC study is Cain Harland

    Cain’s coding, development and insight enable people to do specific tasks on a computer in an easy-to-use, pragmatic manner.

  • “What I enjoy most about programming is the problem-solving and creative nature of the work.”

    MEET CAIN